It is recently reported that the Milner Therapeutics Institute, a first-hand global therapeutic association, has merged with Cambridge based bio data management business Genestack to generate an ecosystem to accelerate the drug discovery and development.
It is stated that Milner Therapeutics will bring together the Babraham Institute, the University of Cambridge and the Wellcome Trust Sanger Institute along with more than 66 affiliated associates, like- pharmaceutical groups Astex, GSK and AstraZeneca.
Smart Genomics Data Management Is the Only Key to the Success and Enhancement of the Project: Believed By Genestack
Imad I. Yassin, the Vice-president of Genestack stated that due to the shrinkage of sequencing technology to a key ring size and also to the genome at single cell level by the emerging technologies, suddenly genomics data could turn into a wearable and streaming dataset. Yassin added that through structural boundaries the data should be managed and the company must have particular strengths between the industry and academic communities. To produce an automated, expandable & robust bio-data platform and tools for permitting the scientists in search of appropriate datasets in cooperation, Genestack had dealt closely with leading academic communities and pharmaceutical companies.
Escalation of Collaborative Research between Industry and Academia
To transform the innovative science into healings and allow the advancement of the innovation from bench to bedside, Milner Therapeutics Institute’s Director Professor Tony Kouzarides, is targeting at the development of a combined research between industry and academia. He also explained that inside an academic ambience, this project would be the channel for drug discovery and by this quote he was creating the scenario easier for educational researchers to deal with the pharmaceutical companies.
As the academic community has the access to disease models and cell lines, it can be utilized to display the drugs for efficiency. Therefore, the drugs can be usable for certain diseases and also can be tested for the use of other diseases and this practice of using and testing drugs is called repurposing or repositioning. If any portfolio in the pharmaceutical company is developing with the pipeline of drug development, this method can be accessible for determining the novel therapeutic agents at an initial stage. This will reduce the cost of early drug discovery.
Effectiveness of Collaborative Research
For the effective usage of this knowledge, the research and academic biologists require convenient tools to investigate, track, aggregate, manage & find this information for accumulating more data than the parts and thus, here Genestack combines.
It is only possible with genestack’s technology to continue with this type of study based on the similar chemical structures. Yassin speaks up that a large number of biologists and chemists are researching on drug development and also consumers for a tiny number of bio-informaticians. And, the motto of them will be forming new sufficient available tools for the discovery scientists, as a result they won’t be wanting of help from any other expert for all problems.
He also adds that with the membership inside the Milner Therapeutics Institute, they have access to a vivacious ecosystem and they also have expectation to work with Milner to hasten the development of their required tools.